Table 3. Seroprevalence of anti-HAV by sex.
2010 | 2011 | 2012 | 2013 | 2014 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Age | M | F | M | F | M | F | M | F | M | F |
0~9 | 61.8 | 65.4 | 45.2 | 56.8* | 65.2 | 69.7 | 62 | 66.5 | 67.5 | 65.4 |
10~19 | 18.1 | 20 | 25.7 | 26.5 | 31.1 | 33.1 | 35.3 | 35.1 | 37.1 | 31.9* |
20~29 | 7.9 | 9.6* | 12.3 | 13.9* | 15.3 | 16.3 | 14.8 | 17.5* | 16.5 | 19.9* |
30~39 | 42.6 | 38* | 38.6 | 32.9* | 35.6 | 30.4* | 33.4 | 29.4* | 31 | 30.5 |
40~49 | 87.2 | 88.4* | 85.4 | 86.3 | 84 | 84.4 | 81.3 | 81.6 | 79.9 | 79.9 |
50~59 | 98.7 | 98.7 | 98.6 | 98.7 | 98.2 | 98.4 | 97.9 | 98.2 | 97.9 | 98.2 |
60~ | 98.8 | 99.4 | 97.7 | 98.9* | 99 | 99.5 | 99.5 | 99.7 | 99.3 | 99.7* |
Total** | 59.3 | 62.7 | 58.3 | 62.6 | 61.5 | 64.2 | 60.5 | 62.7 | 61.0 | 63.2 |
*Positivity of anti-HAV was significantly different between males and females (p < .05 by the chi-square test)
**Seroprevalence of anti-HAV was adjusted by age and area.